Filing Details

Accession Number:
0001209191-17-026664
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-04-12 16:12:22
Reporting Period:
2017-04-10
Filing Date:
2017-04-12
Accepted Time:
2017-04-12 16:12:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1293971 Bluebird Bio Inc. BLUE Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1578251 T. Jeffrey Walsh C/O Bluebird Bio, Inc.
150 Second Street
Cambridge MA 02141
Chief Financial No Yes No Yes
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-04-10 1,250 $5.50 28,555 No 4 M Direct
Common Stock Disposition 2017-04-10 1,250 $87.38 27,305 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2017-04-10 1,250 $0.00 1,250 $5.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
90,635 2023-01-16 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016.
  2. The range of prices for the transaction reported on this line was $87.05 to $87.90. The average weighted price was $87.3802. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. This option to purchase shares of our common stock granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years.